Cg Oncology Inc (CGON) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Cg Oncology Inc (CGON) following the 2026 Q2 hedge fund 13F filings?

As of today, CGON has moved +2.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +1.4% for the XLV sector ETF — an outperformance of +1.0%. Since the quarter end (June 30, 2026), CGON gained +8.1% vs +6.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Cg Oncology Inc (CGON)

224 + Investors. Track Smart Money conviction in CGON. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CGON

Based on 232 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their CGON positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🏔️

At the ownership peak (98% of max)

98% of all-time peak

232 hedge funds hold CGON right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +44% more funds vs a year ago

fund count last 6Q

+71 new funds entered over the past year (+44% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 53% buying

132 buying117 selling

Last quarter: 132 funds bought or added vs 117 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-26 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 34 → 43 → 65 → 39. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 29% long-term, 38% new

■ 29% conviction (2yr+) ■ 34% medium ■ 38% new

Of the 232 current holders: 67 (29%) held >2 years, 78 held 1–2 years, and 87 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

📈

Growing discovery — still being found

41 → 34 → 43 → 65 → 39 new funds/Q

New funds entering each quarter: 34 → 43 → 65 → 39. A growing number of institutions are discovering CGON each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

📊

Mixed cohorts — 28% veterans, 48% new entrants

■ 28% veterans ■ 25% 1-2yr ■ 48% new

Of 240 current holders: 66 (28%) held 2+ years, 60 held 1–2 years, 114 (48%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

🏆

Elite ownership — 45% AUM from top-100 funds

45% from top-100 AUM funds

54 of 226 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in CGON. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.5

out of 10

Moderate Exit Risk

Exit risk score 4.5/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	224	236	-5.08%
13F Shares	99M	92M	7.15%
Total Value	$6.15B	$5.44B	13.08%
New Positions	39	65	-26
Increased Positions	91	83	+8
Closed Positions	45	24	+21
Reduced Positions	71	61	+10
Total Calls	10	9	11.11%
Total Puts	4	4	-
PUT/CALL Ratio	0.4	0.44	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

224

236

-5.08%

13F Shares

99M

92M

7.15%

Total Value

$6.15B

$5.44B

13.08%

New Positions

-26

Increased Positions

Closed Positions

+21

Reduced Positions

+10

Total Calls

11.11%

Total Puts

PUT/CALL Ratio

0.4

0.44

Bullish

Institutional Holders (2026 Q2)

224 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CGON. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CGON holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Decheng Capital LLC	61.87%	6,371,669	$452.7M
2	Foresite Capital Management VI LLC	26.20%	2,369,574	$168.4M
3	Seven Fleet Capital Management LP	22.12%	1,886,236	$134.0M
4	Acorn Capital Advisors, LLC	21.94%	1,131,500	$80.4M
5	Foresite Capital Management V, LLC	21.17%	1,079,050	$76.7M
6	Avidity Partners Management LP	15.92%	1,398,948	$99.4M
7	TCG Crossover Management, LLC	6.27%	3,670,206	$260.8M
8	Rtw Investments, LP	5.16%	8,514,590	$605.0M
9	EcoR1 Capital, LLC	5.16%	1,494,300	$106.2M
10	DV Trading LLC	3.35%	1,439,393	$102.3M
11	Logos Global Management LP	3.06%	1,000,000	$71.0M
12	Stempoint Capital LP	1.95%	159,349	$11.3M
13	EcoR1 Capital, LLC	1.94%	561,500	$39.9M
14	Orbimed Advisors LLC	1.28%	972,800	$69.1M
15	PFM Health Sciences, LP	0.78%	128,286	$9.1M
16	Bellevue Group AG	0.74%	493,596	$35.1M
17	Caption Management, LLC	0.59%	1,779,200	$126.4M
18	ArrowMark Colorado Holdings LLC	0.46%	155,354	$11.0M
19	Lynx1 Capital Management LP	0.44%	31,391	$2.2M
20	Sicart Associates LLC	0.43%	25,000	$1.8M
21	Caption Management, LLC	0.40%	1,195,200	$84.9M
22	ADAR1 Capital Management, LLC	0.39%	118,664	$8.4M
23	Ground Swell Capital, LLC	0.37%	4,765	$339K
24	Jefferies Financial Group Inc.	0.36%	769,947	$54.7M
25	Eventide Asset Management, LLC	0.35%	369,839	$26.3M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Cg Oncology Inc (CGON)

What does the Smart Money Trend signal show for CGON?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CGON positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CGON?

Slight buying edge — 53% buying: Last quarter: 132 funds bought or added vs 117 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CGON holders?

Elite ownership — 45% AUM from top-100 funds: 54 of 226 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in CGON. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CGON?

Mixed — 29% long-term, 38% new: Of the 232 current holders: 67 (29%) held >2 years, 78 held 1–2 years, and 87 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Cg Oncology Inc (CGON) following the 2026 Q2 hedge fund 13F filings?

As of today, CGON has moved +2.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +1.4% for the XLV sector ETF — an outperformance of +1.0%. Since the quarter end (June 30, 2026), CGON has gained +8.1% vs +6.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Cg Oncology Inc (CGON)

Smart Money Signals — CGON

Selling streak — 1 quarter in a row

At the ownership peak (98% of max)

Fast accumulation — +44% more funds vs a year ago

Slight buying edge — 53% buying

Fewer new buyers each quarter (-26 vs last Q)

Mixed — 29% long-term, 38% new

Growing discovery — still being found

Mixed cohorts — 28% veterans, 48% new entrants

Elite ownership — 45% AUM from top-100 funds

Institutional Sentiment Summary — CGON

Hedge Fund Ownership: CGON

Market Analysis: CGON

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CGON

Is It Too Late to Buy Cg Oncology Inc (CGON) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: CGON

Statistics: CGON

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Cg Oncology Inc (CGON)

Welcome to 13Foresight!